Mr. Kevin T. Collins, J.D. is a Partner at Jenner & Block LLP. Previously, Mr. Collins served as a Shareholder at Heller Ehrman LLP since 2005 and was a Member of the Corporate/VLG Practice Group. Mr. Collins's areas of practice include Capital Markets, Life Sciences, Mergers and Acquisitions, and Venture Law Group/Emerging Companies. He focuses his practice on representing companies in the life sciences and healthcare sectors. Mr. Collins' representation for these companies covers general corporate matters, securities law, SEC registered offerings and private placements, strategic partnering, and licensing. His life science clients include large pharmaceutical companies, such as Bayer Healthcare, publicly-traded biotech and specialty pharmaceutical companies, such as Enzon Pharmaceuticals, Obagi Medical Products, Osteotech and Alfacell, and leading privately-held life science companies such as Helicon Therapeutics, Tengion, and Aerovance. Some of Mr. Collins' representative engagements include his representation of the Obagi Medical Products Inc. in its initial public offering; of Enzon Pharmaceuticals in its license agreement with Schering-Plough for PEG-Intron; of Bayer Healthcare LLC in its license and collaboration agreement with Regeneron Pharmaceuticals for VEGF Trap; of Osteotech in its strategic alliances and marketing agreements with Musculoskeletal Transplant Foundation, Smith & Nephew and Depuy; and many more. He is admitted to practice law at the Bar of New York, The United States District Court for the Southern District of New York, and State Courts of New York. Mr. Collins received his J.D. from the Seton Hall University School of Law in 1980 and a B.A. in Communications from the Fordham University in 1976.